LOS ANGELES, Nov. 27, 2019 /PRNewswire/ -- The biotech sector continues to grow as valuations are sky high, based on recent M&A's within the industry. 2019 started off with a boom with the announcement of two multi-billion-dollar deals valued at a total $82 billion, one of them being among the top 10 highest valuations of all time in the sector.
The sector continues to expand rapidly with new discoveries, IP and tech. Experts and fund managers alike believe that the growth and success of biotech is not just another bubble. The sector holds a number of well known companies looking to develop the industry's next big drug therapy such as ChemoCentryx, Inc. (NASDAQ: CCXI), Akero Therapeutics, Inc. (NASDAQ: AKRO) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN).
'Regulators are pressuring companies to cut drug costs and takeovers have become the preferred method of combating looming patent expiries on some of the top-selling medicines they have relied upon in recent years' says Ivo Staijen, manager of the HBM Global Biotechnology fund.
Innovative companies in the industry, like Oncolytics Biotech (NASDAQ: ONCY) are adopting changes that are helping to transform the sector. Oncolytics develops treatments for cold tumor identification through Pelareorep. Clinical trials have provided us with a multitude of observations and conclusions thus far regarding the effectiveness of pelareorep in normal cells versus cancerous cells.
'Virtually no other sector offers long-term investors better growth prospects than biotechnology', says Mario Linimeier, a managing director at Medical Strategy, whose funds include Medical BioHealth.
The M&A deals in the sector accounted for roughly half of the $173.326 billion USD in 14 biopharma drug-based M&A deals recorded for the first half of 2019. This doesn't include the earlier deals which closed in 2019, such as Takeda Pharmaceutical's $58.6 billion USD purchase of Shire.
The largest of acquisition this year was Novartis' up-to-$1.575 billion USD purchase of IFM Tre, a subsidiary of IFM Therapeutics. That acquisition expanded Novartis' pipeline with one clinical and two preclinical programs designed to treat chronic inflammation by inhibiting targets in the body.
'Most investors have exposure to the large pharmaceutical giants but from a value creation perspective they should be invested in earlier-stage companies too. Biotechnology is the backbone of innovation these days,' says Staijen
For some, that would mean backing giants like New Jersey-based Celgene who develops and markets drug treatments for inflammatory disorders and cancer. Like Seattle Genetics, Celgene also has a flagship product: Revlimid. This drug is approved for the treatment of multiple myeloma and certain types of transfusion-dependent anemias.
The pros have pointed to three main areas where investors can position themselves in this dynamic and fluid market; through tech, through unique drugs and treatments and IP - this is what fills the pipeline.
What's In The Pipeline?
Investors considering buying a biotech stock need to study the potential of its current products and its pipeline, which refers to the portfolio of the company's experimental drugs in development.
The IP that drives biotech may be one of the easy entry points for early investors to look at. Oncolytics Biotech (NASDAQ: ONCY) has also solidified a strategic partnership with Pfizer to study its Pelareorep treatment with plans to develop innovative immunotherapy combinations tackling the most challenging cancers, which could lead to very valuable IP.
Oncolytics Biotech's treatment induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers. The company is looking to enter phase 3 testing come 2020.
Being Creative With Your Picks
There are a number of existing companies, like Oncolytics Biotech (ONCY) that originate in Canada and then co-list on the NASDAQ. This is a great place to seek out competitive biotech companies that have captured the interest of the industry.
If biotech can reach the kind of massive revenue numbers the current data suggests, some of these newcomers may become the future giants of the industry that come to define the future of biotech.
Companies already seeking to take an active lead in this sector include:
ChemoCentryx (NASDAQ: CCXI) develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
ChemoCentryx recently announced very positive news announcing "ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan's Superiority Over Standard of Care in ANCA-Associated Vasculitis" which has sent shares of ChemoCentryx soaring. Yet another example of how high this sector can go.
Akero Therapeutics (NASDAQ: AKRO) is developing medicines to reverse the course of serious metabolic diseases. Right now, that means advancing the company's lead program, AKR-001, to provide a powerful new therapy for patients with NASH (non-alcoholic steatohepatitis) – a fatty liver disease.
Alexion (NASDAQ: ALXN) is the maker of Soliris, a drug used to treat multiple rare disorders affecting the complement system. Based in Boston since 2018, Alexion remains heavily involved in immune system research as it relates to autoimmune diseases.
For more on Oncolytics Biotech and the broader biotech industry, view the report at USA News Group: https://usanewsgroup.com/2019/10/06/what-if-you-could-teach-your-body-to-fight-cancer/
This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of USA News Group only and are subject to change without notice. USA News Group assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.
DISCLAIMER: USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact Information:
FN Media Group, LLC
e-mail: [email protected]
U.S. Phone: +1(954)345-0611
SOURCE USA News Group